Independent second opinion. Before you commit capital.
A structured products desk pitched you a trade. Your internal team likes it. But pricing one of these well takes someone who has spent years building and hedging the same structures, seeing how the pricing actually works.
Verio Labs provides independent trade analysis from someone who spent years pricing and hedging these structures and knows where the margin sits. No conflicts, nothing to sell.
What your current providers miss.
Sell-side desks are good at what they do. The pricing is competitive, the structuring is creative, and the pitch decks are polished. What they don't do is tell you where the margin sits in the trade, whether the vol markup is reasonable, or if there's a simpler structure that gets you 90% of the payoff at half the cost. That's not a criticism of your bank. It's just not their job. It is ours.
What we do for asset managers.
Scoped to your needs, delivered as auditable artifacts.
Trade structure analysis
Before you commit capital, get a desk-style decomposition: what you're actually long and short, where the margin is embedded, how the pricing compares to vanilla alternatives, and what the Greeks look like under stress.
Scenario stress testing
Historical replays and forward-looking scenarios translated into P&L impact. What breaks first in your portfolio, and what's the marginal risk of adding this trade?
Structured note review
Independent decomposition of any structured note or product. Cost analysis, payoff scenarios, and a clear assessment of whether the complexity is earning its keep versus a simpler alternative.
Go deeper on your own.
Educational tools built from the same expertise that powers our advisory work.
New to options Greeks?
Our interactive course breaks down Delta, Gamma, Theta, Vega, and Rho through cinematic visualizations and live Black-Scholes math.
Exploring tail risk hedging?
Start with our comprehensive practitioner guide and AI-powered readiness assessment covering strategies, instruments, and governance.
Illustrative and for information only. Any figures are model-based estimates under stated assumptions, not appraisals or assurances of value; any backtests are hypothetical and not a predictor of results; case studies are anonymized and representative. Nothing here is investment advice or a recommendation to buy or sell any security. See our full disclosures.